Dbait and uses thereof

Details for Australian Patent Application No. 2007298990 (hide)

Owner Institut Curie Centre National de la Recherche Scientifique Museum National D'Histoire Naturelle INSERM (Institut National de la Sante et de la Recherche Medicale)

Inventors Sun, Jian-Sheng; Dutreix, Marie

Agent Davies Collison Cave

Pub. Number AU-B-2007298990

PCT Pub. Number WO2008/034866

Priority 11/524,528 21.09.06 US

Filing date 20 September 2007

Wipo publication date 27 March 2008

Acceptance publication date 26 July 2012

International Classifications

A61K 31/713 - Double-stranded nucleic acids or oligonucleotides

A61K 47/48 Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

A61P 35/00 Antineoplastic agents

C07H 21/00 Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

C12N 15/113 Mutation or genetic engineering - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Event Publications

19 March 2009 PCT application entered the National Phase

  PCT publication WO2008/034866 Priority application(s): WO2008/034866

26 July 2012 Application Accepted

  Published as AU-B-2007298990

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007298991-Device and method for detecting an anomaly in an assembly of a first and a second object

2007298987-Sulfonylpyrazoline carboxamidine derivatives as 5-HT6 antagonists